Abstract
Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.
Keywords: Aspirin, clopidogrel, prasugrel, ticagrelor, antiplatelet agents, P2Y12 inhibitors.
Current Pharmaceutical Design
Title:Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor
Volume: 22 Issue: 13
Author(s): Paul P. Dobesh, Sara Varnado and Meagan Doyle
Affiliation:
Keywords: Aspirin, clopidogrel, prasugrel, ticagrelor, antiplatelet agents, P2Y12 inhibitors.
Abstract: Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.
Export Options
About this article
Cite this article as:
Dobesh P. Paul, Varnado Sara and Doyle Meagan, Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor, Current Pharmaceutical Design 2016; 22 (13) . https://dx.doi.org/10.2174/1381612822666151208120106
DOI https://dx.doi.org/10.2174/1381612822666151208120106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pediatric Takayasu Arteritis: A Review of the Literature
Current Pediatric Reviews Halitosis Vaccines Targeting FomA, a Biofilm-bridging Protein of Fusobacteria nucleatum
Current Molecular Medicine Special Features of Gram-Positive Bacterial Eradication by Photosensitizers
Recent Patents on Anti-Infective Drug Discovery Nitric Oxide: A Key Mediator of Biofilm Dispersal with Applications in Infectious Diseases
Current Pharmaceutical Design Role of Old Antibiotics in Multidrug Resistant Bacterial Infections
Current Drug Targets Recent Advances in Natural Product-Based Anti-Biofilm Approaches to Control Infections
Mini-Reviews in Medicinal Chemistry Heart Failure in South America
Current Cardiology Reviews New Approaches to Develop Anti-Staphylococcal Agents
Current Medicinal Chemistry - Anti-Infective Agents New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Discovery of Medically Significant Lantibiotics
Current Drug Discovery Technologies Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Bacteremic Streptococcus pneumoniae in Community-Acquired Pneumonia: An Update
Current Respiratory Medicine Reviews Concurrent Methicillin-Resistant <i>Staphylococcus aureus Septicemia</i> and Thyroid Abscess in a Young Male with Dengue
Infectious Disorders - Drug Targets Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy The Use of Phages for the Removal of Infectious Biofilms
Current Pharmaceutical Biotechnology Vaccine Therapy for P. acnes-Associated Diseases
Infectious Disorders - Drug Targets